Int. J. Mol. Sci. 2013, 14(7), 13893-13908; doi:10.3390/ijms140713893

Sarcosine as a Potential Prostate Cancer Biomarker—A Review

1 Central European Institute of Technology, Brno University of Technology, Technicka 3058/10, CZ-61600 Brno, Czech Republic 2 Department of Chemistry and Biochemistry, Faculty of Agronomy, Mendel University in Brno, Zemedelska 1, CZ-61300 Brno, Czech Republic 3 Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-61200 Brno, Czech Republic 4 Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University, and University Hospital Motol, V Uvalu 84, CZ-15006 Prague 5, Czech Republic 5 Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, CZ-12840 Prague 2, Czech Republic
* Author to whom correspondence should be addressed.
Received: 22 May 2013; in revised form: 20 June 2013 / Accepted: 22 June 2013 / Published: 4 July 2013
(This article belongs to the Special Issue Molecular Research in Urology)
PDF Full-text Download PDF Full-Text [520 KB, Updated Version, uploaded 5 July 2013 16:55 CEST]
The original version is still available [520 KB, uploaded 4 July 2013 12:26 CEST]
Abstract: Prostate cancer (CaP) is the most common type of tumour disease in men. Early diagnosis of cancer of the prostate is very important, because the sooner the cancer is detected, the better it is treated. According to that fact, there is great interest in the finding of new markers including amino acids, proteins or nucleic acids. Prostate specific antigen (PSA) is commonly used and is the most important biomarker of CaP. This marker can only be detected in blood and its sensitivity is approximately 80%. Moreover, early stages cannot be diagnosed using this protein. Currently, there does not exist a test for diagnosis of early stages of prostate cancer. This fact motivates us to find markers sensitive to the early stages of CaP, which are easily detected in body fluids including urine. A potential is therefore attributed to the non-protein amino acid sarcosine, which is generated by glycine-N-methyltransferase in its biochemical cycle. In this review, we summarize analytical methods for quantification of sarcosine as a CaP marker. Moreover, pathways of the connection of synthesis of sarcosine and CaP development are discussed.
Keywords: cancer of prostate; biomarkers; early diagnostic; prostatic specific antigen; non-invasive markers; urine; amino acids

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Cernei, N.; Heger, Z.; Gumulec, J.; Zitka, O.; Masarik, M.; Babula, P.; Eckschlager, T.; Stiborova, M.; Kizek, R.; Adam, V. Sarcosine as a Potential Prostate Cancer Biomarker—A Review. Int. J. Mol. Sci. 2013, 14, 13893-13908.

AMA Style

Cernei N, Heger Z, Gumulec J, Zitka O, Masarik M, Babula P, Eckschlager T, Stiborova M, Kizek R, Adam V. Sarcosine as a Potential Prostate Cancer Biomarker—A Review. International Journal of Molecular Sciences. 2013; 14(7):13893-13908.

Chicago/Turabian Style

Cernei, Natalia; Heger, Zbynek; Gumulec, Jaromir; Zitka, Ondrej; Masarik, Michal; Babula, Petr; Eckschlager, Tomas; Stiborova, Marie; Kizek, Rene; Adam, Vojtech. 2013. "Sarcosine as a Potential Prostate Cancer Biomarker—A Review." Int. J. Mol. Sci. 14, no. 7: 13893-13908.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert